E
VINC

Ergoteles’s Vincerx Pharma, Inc. Common Stock VINC Stock Holding History

Ergoteles’s Portfolio VINC Stock Details VINC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-3,551
Closed -$98K – 1981
2022
Q3 		$98K Sell
3,551
-484
-12% -$13.9K ﹤0.01% 1389
2022
Q2 		$107K Buy
+4,035
New +$179K ﹤0.01% 1483

Other funds holding VINC

Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
SRC
Sage Rhino Capital Menlo Park, California $535M AUM 24.07% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Ergoteles's VINC Position: Q4 2022 in Review

Ergoteles sold out of Vincerx Pharma, Inc. Common Stock (VINC) in Q4 2022, closing a stake of 3,551 shares — an estimated $98K sold.

Ergoteles first reported a position in VINC in Q2 2022 and held it in 2 quarters. The position peaked at $107K in Q2 2022. 35 funds tracked by Wall St. Rank hold VINC as of Q4 2022.

  • Ergoteles reported no remaining Vincerx Pharma, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • Ergoteles sold 3,551 Vincerx Pharma, Inc. Common Stock shares in Q4 2022, an estimated $98K.
  • Ergoteles first reported a position in Vincerx Pharma, Inc. Common Stock in Q2 2022 and held it in 2 quarters.
  • Ergoteles's Vincerx Pharma, Inc. Common Stock position peaked at $107K in Q2 2022.
  • 35 funds tracked by Wall St. Rank held Vincerx Pharma, Inc. Common Stock as of Q4 2022.

Based on Ergoteles's 13F filing for Q4 2022, filed 14 Feb 2023.